Product Name
Monophosphoryl lipid A (MPLA) (Synthetic, TLR4/Th1, vaccine adjuvant)
Subclassification
Adjuvants for protein-based vaccines
Storage
Shipped at room temperature and it should be stored at -20°C. Avoid repeated freeze thaw cycles.
Recommended Usage
Add 1 ml of DMSO to 1 mg MPLA and vortex until complete solubilization. Solutions can be further diluted to the desired working concentration with sterile endotoxin free water.
Description
MPL adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of lipopolysaccharide. It has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. MPL is a potent stimulator of T cell and antibody responses.
MPL has been shown to be capable of binding and activating Toll-like receptor-4 (TLR-4), present on key antigen-presenting cells, which play an important role in the induction of the innate and subsequent adaptive immune responses. Recent observations suggest that MPL, directly affects adaptive immune responses via specific interactions with B cells.
MPL is the first and only TLR ligand in licensed human vaccines, in the form of AS04. MPL is licensed in Europe for allergy treatment Pollinex Quattro. With over 33,000 doses administered to date, MPL adjuvant has emerged as a safe and effective vaccine adjuvant.
Synthetic lipid A from E. coli (MPLAs) is a pure monophosphoryl lipid A compound produced by chemical synthesis. MPLAs activates TLR4 but does not activate TLR2 reflecting its high purity. MPLAs contains 6 fatty acyl groups, while MPLA purified from bacteria contains a mixture of 5, 6,and 7 acyl lipid A. Formula: C96H184N3O22P
Solubility: DMSO (1 mg/ml)
Working concentration: 10 ng - 1 μg/ml
Preparation : Synthetic lipid A from E-coli.
Format
Provided as a lyophilized powder; sterile. Colorless, odorless white powder
Loading ......
